Filter by Category: In Vitro Activity
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the USA (2013-2014).
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the USA (2013-2014). by Duncan LR, Sader HS, Flamm RK, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 303-306
In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014)
In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from United States medical centers by Census region (2014).
In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from United States medical centers by Census region (2014). by Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN and Sader HS. published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2537-2541
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. by Flamm RK, Nichols WW, Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents. 2016; 47 (3): 235-242
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. by Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M and Yamano Y published in J. Antimicrob. Chemother. 2016; 71 (3): 670-677
In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study.
In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study. by Armstrong ES, Farrell DJ, Palchak M and Steenbergen JN published in Antimicrob. Agents. Chemother. 2016; 60 (1): 666-668
In Vitro Activity of Delafloxacin Tested Against Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis
In Vitro Activity of Delafloxacin Tested Against Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis, Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Activity of Lefamulin, an Pleuromutilin Derivative, against S. aureus Strains with Decreased Susceptibility to Vancomycin
Activity of Lefamulin, an Pleuromutilin Derivative, against S. aureus Strains with Decreased Susceptibility to Vancomycin, Lead author: Sader HS, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Solithromycin MIC and Disk Diffusion Quality Control Ranges, a CLSI Multi-Laboratory M23-A3 Study Design
Solithromycin MIC and Disk Diffusion Quality Control Ranges, a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Ross JE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA
Performance of BD MAX™ StaphSR against S. aureus Clinical Isolates from the 9 USA Census Regions
Performance of BD MAX™ StaphSR against S. aureus Clinical Isolates from the 9 USA Census Regions, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA